Esperion combines excellence in drug development with superior business skills to deliver first-in-class, oral, low-density, lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers. This is possible only through the considerable experience, expertise, and commitment of our exceptional leaders and colleagues. We also have deep and broad relationships with other industry-leading experts and businesses, enabling us to extend our impact where and when needed. We know what is required for success and how to achieve it.
President and Chief Executive Officer
Tim Mayleben is President and Chief Executive Officer and has been a member of our board of directors since February 2010. Prior to joining Esperion, Tim was President, CEO and a Director of Aastrom Biosciences, Inc. (NASDAQ: ASTM). Previously, Tim was President, Chief Operating Officer and a director of NightHawk Radiology Holdings, Inc. Prior to joining Nighthawk, Tim was the COO of the original Esperion, until its acquisition by Pfizer in 2004. Tim is an advisor to, investor in, and member of the board of directors of several life science companies, including Kaléo Pharma, Loxo Oncology, Lycera Corporation, Marinus Pharmaceuticals and the Wolverine Venture Fund. Tim earned an MBA, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a BBA from the University of Michigan, Ross School of Business.
Roger Newton, PhD, FAHA
Executive Chairman and Chief Scientific Officer
Roger Newton is founder, Executive Chairman and Chief Scientific Officer of Esperion and is a fellow of the American Heart Association. Prior to founding Esperion in 2008, Roger was Senior Vice President, Pfizer Global R&D from 2004 to 2008. Previously, Roger was Co-founder, President & CEO of the original Esperion from July 1998 until its acquisition by Pfizer in 2004. Prior to founding the original Esperion, Roger was Chairman of the Atherosclerosis Drug Discovery Team at Warner Lambert from 1981 to 1998. Roger is a director of a number of life science companies including DeNovo Sciences, Juventas Therapeutics, Inc. and Rubicon Genomics, Inc. and is also a member of the Technology Advisory Boards for Arboretum Ventures and Metagenics, Inc. Roger earned a Ph.D. in Nutrition from the University of California, Davis, an M.S. in Nutritional Biochemistry from the University of Connecticut, and a B.S. in Biology from Lafayette College.
Narendra Lalwani, PhD, MBA
Executive Vice President, Research & Development, and Chief Operating Officer
Narendra Lalwani is Executive Vice President, R & D, and Chief Operating Officer. Prior to joining Esperion, Narendra was Chief Scientific Officer at Cerenis Therapeutics from 2007 to 2014 where he led R&D activities for the company. Previously, Narendra was Vice President of Drug Safety at the original Esperion until its acquisition by Pfizer. Prior to Esperion, Narendra held various positions of increasing responsibility in the Department of Pathology and Experimental Toxicology at Warner-Lambert/Parke-Davis. Narendra is a Fellow of American Heart Association (FAHA) and a diplomate of the American board of Toxicology (DABT). Narendra earned a Ph.D. in Biophysics from the University of Bombay (India) and an MBA from the University of Michigan, Ross School of Business.
Mary McGowan, MD
Chief Medical Officer
Mary McGowan is Chief Medical Officer. Prior to joining Esperion, Mary held senior positions in the cardiovascular group at Genzyme/Sanofi. Before moving to industry, Mary spent 20 years as the director of a large lipid disorders clinic in New Hampshire and continues to see patients twice monthly at the Dartmouth Hitchcock Lipid Clinic in Lebanon, NH. Mary has been the PI on many national and international lipid lowering trials and served as a board member of the National Lipid Association for 5 years. She was the Chief Medical Officer of the Familial Hypercholesterolemia Foundation and also served on the National Lipid Association’s Expert Panel on Familial Hypercholesterolemia, the New Hampshire Childhood Obesity Expert Panel and New Hampshire board of the American Heart Association. Mary has written many articles in peer reviewed journals on lipid metabolism and has authored 5 books for the lay press including Heart Fitness for Life (Oxford University Press) and 50 Ways to Lower Your Cholesterol (McGraw-Hill), and serves as a reviewer for the Journal of Clinical Lipidology. Mary completed medical school and residency training at the University of Massachusetts Medical Center and a fellowship at Johns Hopkins.
Senior Vice President, Strategic Marketing and Product Planning
Marianne Andreach is Senior Vice President of Strategic Marketing and Product Planning. Prior to joining Esperion, Marianne was a consultant in the pharmaceutical industry. Previously, she was Senior Director, Business Development and Team Lead, MDCO-216 (ApoA-I Milano) at The Medicines Company. Marianne also worked in Medical Affairs at Pfizer Global R&D, and led Marketing and Product Planning at the original Esperion Therapeutics. Additionally, Marianne has worked in a variety of marketing and product planning roles at Bristol-Myers Squibb and Parke-Davis, including working on the launch teams for both Pravachol and Lipitor, as well as supporting both Plavix and Glucophage. Marianne earned a BA in Biology/History from the College of the Holy Cross.
Vice President, Global Regulatory Affairs
Ashley Hall is Vice President of Global Regulatory Affairs. Prior to joining Esperion, Ashley was Global Regulatory Lead for Cardiovascular at Amgen, and oversaw the regulatory strategy and global filings for the evolocumab program leading to the world’s first approval of a PCSK9 inhibitor for cholesterol lowering. Previously, Ashley was Vice President of Regulatory Affairs at Micromet, which was acquired by Amgen in March of 2012. Prior to joining Micromet, she was Vice President of Regulatory and Clinical Affairs at RevoGenex and previously, Director of World Wide Regulatory Affairs with the oncology team at MedImmune. Ashley held various roles of increasing responsibility in global Regulatory Affairs at Abraxis BioScience and at La Jolla Pharmaceutical Company. Ashley has also worked in Global Regulatory Policy at Amgen and as a policy intern for Francis Collins at the National Human Genome Institute. Ashley earned her Juris Doctorate at the University of San Diego School of Law and her Bachelors of Science in Biochemistry and Cell Biology at the University of California San Diego.
Vice President, Finance
Rick Bartram is Vice President of Finance. Prior to joining Esperion, Rick was Assurance Manager with PricewaterhouseCoopers (PwC) where he held various positions of increasing responsibility over almost eight years with the firm. Rick earned both Masters and Bachelors degrees in accounting from Michigan State University, and is a Certified Public Accountant.